Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin effects on sortilin, glycemic indices, and lipid profile in type 2 diabetes
IRCT20231122060137N1Phase 3Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Serum sortilin level, Blood glucose indices and 2 more. Started Oct 2023; status: completed.
02
Drugs
atorvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20231122060137N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231122060137N1.